These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29254734)

  • 21. Why dystrophin quantification is key in the eteplirsen saga.
    Aartsma-Rus A; Arechavala-Gomeza V
    Nat Rev Neurol; 2018 Aug; 14(8):454-456. PubMed ID: 29967362
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical management of muscle weakness in Duchenne muscular dystrophy.
    Rivera SR; Jhamb SK; Abdel-Hamid HZ; Acsadi G; Brandsema J; Ciafaloni E; Darras BT; Iannaccone ST; Konersman CG; Kuntz NL; McDonald CM; Parsons JA; Tesi Rocha C; Zaidman CM; Butterfield RJ; Connolly AM; Mathews KD
    PLoS One; 2020; 15(10):e0240687. PubMed ID: 33075081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exon skipping therapy for Duchenne muscular dystrophy.
    Kole R; Krieg AM
    Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].
    Dal-Ré R; Lopez de Munain A; Ayuso C
    Rev Neurol; 2017 Oct; 65(8):373-380. PubMed ID: 28990648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy.
    Iff J; Gerrits C; Zhong Y; Tuttle E; Birk E; Zheng Y; Paul X; Henricson EK; McDonald CM;
    Muscle Nerve; 2022 Sep; 66(3):262-269. PubMed ID: 35715998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eteplirsen (Exondys 51) for duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2016 Nov; 58(1507):145-146. PubMed ID: 27805575
    [No Abstract]   [Full Text] [Related]  

  • 28. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line.
    Dowling JJ
    Nat Rev Neurol; 2016 Dec; 12(12):675-676. PubMed ID: 27857122
    [No Abstract]   [Full Text] [Related]  

  • 29. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
    Mah JK
    Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice.
    Stein CA
    Mol Ther; 2016 Nov; 24(11):1884-1885. PubMed ID: 27916994
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 33. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
    Lee J; Echigoya Y; Duddy W; Saito T; Aoki Y; Takeda S; Yokota T
    PLoS One; 2018; 13(5):e0197084. PubMed ID: 29771942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duchenne muscular dystrophy drugs face tough path to approval.
    Hodgkinson L; Sorbera L; Graul AI
    Drugs Today (Barc); 2016 Mar; 52(3):199-202. PubMed ID: 27186594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duchenne Muscular Dystrophy: A Practice Update.
    Suthar R; Sankhyan N
    Indian J Pediatr; 2018 Apr; 85(4):276-281. PubMed ID: 28653137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.
    Kesselheim AS; Avorn J
    JAMA; 2016 Dec; 316(22):2357-2358. PubMed ID: 27775756
    [No Abstract]   [Full Text] [Related]  

  • 39. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.
    Gissy JJ; Johnson T; Fox DJ; Kumar A; Ciafaloni E; van Essen AJ; Peay HL; Martin A; Lucas A; Finkel RS;
    Neuromuscul Disord; 2017 Oct; 27(10):905-910. PubMed ID: 28739181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.